Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery

 

PDF Download Buy Article Permissions and Reprints

Summary

Purer factor IX (FIX) concentrates have been produced for the treatment of hemophilia B in the attempt to reduce the risk of thrombotic complications associated with the use of prothrombin complex concentrates. To evaluate ex vivo whether or not FIX concentrates activate the coagulation system in conditions associated with a high risk for thrombosis, we measured markers of hypercoagulability in 10 patients with hemophilia B who underwent surgery, mainly orthopedic procedures, covered by multiple concentrate infusions (40-80 U/kg/day). Postinfusion plasma levels of prothrombin fragment 1+2 and factor X activation peptide did not differ significantly from the presurgical levels, neither before nor after each concentrate dose. Therefore, it appears that prolonged treatment of patients with hemophilia B undergoing high risk surgical procedures with high doses of FIX concentrate does not cause systemic activation of coagulation. This suggests that purified FIX concentrates are preferable to prothrombin complex concentrates for conditions associated with an increased risk of thrombosis.

• References

• 1 Kasper CK. Clinical use of factor IX concentrates: Report on thromboembolic complications. Thromb Diathes Haemorrh 1975; 33: 640-2
  PubMedGoogle Scholar
• 2 Ccdcrbaum AI, Blatt PM, Roberts HR. Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med 1976; 84: 683-7
  CrossrefPubMedGoogle Scholar
• 3 Gruppo RA, Bove KE, Donaldson VH. Fatal myocardial necrosis associated with prothrombin complex concentrate therapy in hemophilia A. N Engl J Med 1983; 309: 242-3
  CrossrefPubMedGoogle Scholar
• 4 Chavin SI, Siegel DM, Rocco Jr TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-9
  CrossrefPubMedGoogle Scholar
• 5 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 suppl (Suppl. 06) 3-5
  PubMedGoogle Scholar
• 6 Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol 1993; 30 suppl (Suppl. 01) 36-40
  PubMedGoogle Scholar
• 7 White GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic material and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-170
  PubMedGoogle Scholar
• 8 Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028-38
  PubMedGoogle Scholar
• 9 Giles AR, Nesheim ME, Hoogendorn H, Tracy PB, Mann KG. The coagulant active phospholipid content is a major determinant of in vitro thrombogenicity of prothrombin complex (factor IX concentrates) in rabbits. Blood 1982; 59: 401-7
  PubMedGoogle Scholar
• 10 Menaché D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyllopoulos DC, Kosow DP. Coagulation factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-7
  PubMedGoogle Scholar
• 11 Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 1993; 121: 394-405
  PubMedGoogle Scholar
• 12 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified Human plasma factor IX: c therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32
  PubMedGoogle Scholar
• 13 Kim HC, Mc Millan CW, White GC, Bergman GE, Saidi P. Clinical experience with a new monoclonal antibody purified factor IX: half-life, recovery and safety in patients with hemophilia B. Semin Hematol 1990; 27 suppl (Suppl. 02) 30-5
  PubMedGoogle Scholar
• 14 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50
  PubMedGoogle Scholar
• 15 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-5
  PubMedGoogle Scholar
• 16 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. BR J Haematol 1991; 79: 606-11
  CrossrefPubMedGoogle Scholar
• 17 Hampton KK, Preston FE, Lowe GDO, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-84
  CrossrefPubMedGoogle Scholar
• 18 Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15
  PubMedGoogle Scholar
• 20 Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and Fl+2. J Biol Chem 1979; 254: 8751-61
  PubMedGoogle Scholar
• 21 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complexes. Blood 1982; 59: 1086-97
  PubMedGoogle Scholar